GSK plc's Nucala (mepolizumab) received European Commission approval on February 6, 2026, for the treatment of chronic obstructive pulmonary disease (COPD), showing a significant reduction in severe exacerbations. This is the first monthly biologic approved in the EU for this condition, providing new treatment options for millions of patients.